B-cell modulators in immunoglobulin A nephropathy
- 1Renal Medicine Associates
- 2Department of Microbiology, University of Alabama at Birmingham, Heersink School of Medicine
- 3Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Heersink School of Medicine
Abstract
Immunoglobulin A nephropathy (IgAN), defined by mesangial immune-complex deposition enriched for galactose-deficient IgA1 (Gd-IgA1), is the most prevalent biopsy-confirmed primary glomerulonephritis worldwide. Advances in mucosal immunobiology and genetics have underscored the role of dysregulated B-cell activity, increased Gd-IgA1 production, and corresponding Gd-IgA1–specific autoantibodies in the pathogenesis of IgAN. Therapeutic strategies targeting the mucosal immune system, particularly pathways involved in B-cell survival and differentiation, offer a specific approach to disease modification based on our understanding of its pathogenesis. Emerging therapies, including agents targeting gut-associated lymphoid tissue, antagonists of B-cell activating factor (BAFF) and/or a proliferation-inducing ligand (APRIL), and B-cell depletion therapies like anti-CD38 monoclonal antibodies, have demonstrated promising positive results across multiple clinical trials at various stages of development. In this review, we highlight targeting the underlying immunology of IgAN pathogenesis and shed light on newly emerging B-cell modulators for the treatment of the disease.
Related
- The Role of the Immunoglobulin Superfamily of Cell Adhesion Molecules in Intellectual Disability
- The early-life determinant LIN28B constrains immunoglobulin light chain secondary rearrangements independent of BCR specificity
- An unexpected cardiac mass related to immunoglobulin G4-related disease
- Structure-Based Discovery of GTP-Enhanced Rab10 Modulators and Their Effects on Alzheimer Disease-Relevant Cellular Phenotypes
- An automated genetic screen identifies modulators of stress-induced sleep in Caenorhabditis elegans
BibTeX
@article{rajasekaran2026bcell,
title = {{B-cell modulators in immunoglobulin A nephropathy}},
author = {Arun Rajasekaran and Jan Novak and Dana V. Rizk},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1843207},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1843207/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - B-cell modulators in immunoglobulin A nephropathy
AU - Arun Rajasekaran
AU - Jan Novak
AU - Dana V. Rizk
PY - 2026
DA - 2026/10/08
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1843207
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1843207/full
AB - Immunoglobulin A nephropathy (IgAN), defined by mesangial immune-complex deposition enriched for galactose-deficient IgA1 (Gd-IgA1), is the most prevalent biopsy-confirmed primary glomerulonephritis worldwide. Advances in mucosal immunobiology and genetics have underscored the role of dysregulated B-cell activity, increased Gd-IgA1 production, and corresponding Gd-IgA1–specific autoantibodies in the pathogenesis of IgAN. Therapeutic strategies targeting the mucosal immune system, particularly pathways involved in B-cell survival and differentiation, offer a specific approach to disease modification based on our understanding of its pathogenesis. Emerging therapies, including agents targeting gut-associated lymphoid tissue, antagonists of B-cell activating factor (BAFF) and/or a proliferation-inducing ligand (APRIL), and B-cell depletion therapies like anti-CD38 monoclonal antibodies, have demonstrated promising positive results across multiple clinical trials at various stages of development. In this review, we highlight targeting the underlying immunology of IgAN pathogenesis and shed light on newly emerging B-cell modulators for the treatment of the disease.
SN - 1664-3224
ER -